General American Investors Co. Inc. Purchases 167,195 Shares of ARS Pharmaceuticals, Inc. $SPRY

General American Investors Co. Inc. lifted its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 29.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 727,154 shares of the company’s stock after purchasing an additional 167,195 shares during the period. General American Investors Co. Inc.’s holdings in ARS Pharmaceuticals were worth $5,839,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of the company. Torren Management LLC purchased a new stake in ARS Pharmaceuticals in the 4th quarter worth $32,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of ARS Pharmaceuticals by 25.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company’s stock worth $56,000 after acquiring an additional 982 shares during the period. Osaic Holdings Inc. boosted its stake in shares of ARS Pharmaceuticals by 52.8% in the second quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock worth $91,000 after acquiring an additional 1,803 shares during the period. Osterweis Capital Management Inc. purchased a new stake in shares of ARS Pharmaceuticals during the fourth quarter worth about $65,000. Finally, BNP Paribas Financial Markets grew its position in shares of ARS Pharmaceuticals by 58.3% during the second quarter. BNP Paribas Financial Markets now owns 6,097 shares of the company’s stock worth $106,000 after purchasing an additional 2,245 shares in the last quarter. Hedge funds and other institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ:SPRY traded up $0.06 during mid-day trading on Friday, reaching $7.94. The stock had a trading volume of 1,397,483 shares, compared to its average volume of 1,836,345. The business’s 50 day moving average price is $8.73 and its 200 day moving average price is $9.19. ARS Pharmaceuticals, Inc. has a 1 year low of $6.66 and a 1 year high of $18.63. The company has a market cap of $788.44 million, a P/E ratio of -3.95 and a beta of 0.95. The company has a current ratio of 4.94, a quick ratio of 4.77 and a debt-to-equity ratio of 2.79.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.08). The firm had revenue of $22.68 million during the quarter, compared to the consensus estimate of $22.20 million. ARS Pharmaceuticals had a negative return on equity of 153.61% and a negative net margin of 200.00%. Research analysts expect that ARS Pharmaceuticals, Inc. will post -1.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, insider Alexander A. Fitzpatrick sold 3,355 shares of the stock in a transaction on Friday, June 12th. The shares were sold at an average price of $10.00, for a total transaction of $33,550.00. Following the completion of the transaction, the insider owned 90,910 shares in the company, valued at $909,100. This trade represents a 3.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Karas sold 25,000 shares of ARS Pharmaceuticals stock in a transaction on Friday, June 12th. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. Following the completion of the transaction, the insider directly owned 12,176 shares of the company’s stock, valued at $121,760. The trade was a 67.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 33.80% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on SPRY shares. Cantor Fitzgerald increased their price objective on shares of ARS Pharmaceuticals from $12.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 28th. Weiss Ratings raised shares of ARS Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 1st. Wall Street Zen raised shares of ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Northland Securities assumed coverage on shares of ARS Pharmaceuticals in a research report on Thursday, April 9th. They set an “outperform” rating and a $25.00 target price for the company. Finally, Leerink Partners cut their target price on shares of ARS Pharmaceuticals from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Thursday, June 25th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, ARS Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.20.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.